TW227563B - - Google Patents

Info

Publication number
TW227563B
TW227563B TW082101580A TW82101580A TW227563B TW 227563 B TW227563 B TW 227563B TW 082101580 A TW082101580 A TW 082101580A TW 82101580 A TW82101580 A TW 82101580A TW 227563 B TW227563 B TW 227563B
Authority
TW
Taiwan
Application number
TW082101580A
Original Assignee
Samdoz Pharmaceutical Factory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samdoz Pharmaceutical Factory filed Critical Samdoz Pharmaceutical Factory
Application granted granted Critical
Publication of TW227563B publication Critical patent/TW227563B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW082101580A 1992-03-03 1993-03-04 TW227563B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84512392A 1992-03-03 1992-03-03

Publications (1)

Publication Number Publication Date
TW227563B true TW227563B (zh) 1994-08-01

Family

ID=25294463

Family Applications (1)

Application Number Title Priority Date Filing Date
TW082101580A TW227563B (zh) 1992-03-03 1993-03-04

Country Status (14)

Country Link
EP (1) EP0564397A1 (zh)
JP (1) JPH0649076A (zh)
KR (1) KR930019642A (zh)
CN (1) CN1076445A (zh)
AU (1) AU3387593A (zh)
CA (1) CA2090635A1 (zh)
CZ (1) CZ30293A3 (zh)
FI (1) FI930922A (zh)
HU (1) HUT63629A (zh)
IL (1) IL104892A0 (zh)
NO (1) NO930739L (zh)
NZ (1) NZ247032A (zh)
TW (1) TW227563B (zh)
ZA (1) ZA931516B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1655289A1 (en) * 2004-11-04 2006-05-10 Embl Quinazoline derivatives, process for their preparation, their use as antimitotics and pharmaceutical compositions comprising said derivatives
HUE027000T2 (en) * 2011-06-10 2016-08-29 Chiesi Farm Spa Compounds with muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CN104119231A (zh) * 2013-04-27 2014-10-29 重庆华邦制药有限公司 二苯甲胺类化合物的制备方法及中间体
US9834525B2 (en) 2014-02-04 2017-12-05 University Of Tennessee Research Foundation Inhibitors of paxillin function and related compositions and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1242863A (en) * 1968-05-10 1971-08-18 Pharmacia As 2,3-DIHYDRO-5H-THIAZOLO[2,3-b]QUINAZOLINES AND PROCESSES FOR THE PREPARATION THEREOF
DE3734909A1 (de) * 1987-10-15 1989-04-27 Boehringer Ingelheim Kg Verwendung von oxochinazolinderivaten bei der behandlung der hyperlipidaemie

Also Published As

Publication number Publication date
CZ30293A3 (en) 1993-12-15
HUT63629A (en) 1993-09-28
CN1076445A (zh) 1993-09-22
HU9300556D0 (en) 1993-05-28
EP0564397A1 (en) 1993-10-06
AU3387593A (en) 1993-09-09
KR930019642A (ko) 1993-10-18
IL104892A0 (en) 1993-07-08
FI930922A0 (fi) 1993-03-02
ZA931516B (en) 1994-09-03
NO930739D0 (no) 1993-03-01
CA2090635A1 (en) 1993-09-04
NZ247032A (en) 1994-11-25
NO930739L (no) 1993-09-06
JPH0649076A (ja) 1994-02-22
FI930922A (fi) 1993-09-04

Similar Documents

Publication Publication Date Title
DK0598561T3 (zh)
DK0652790T3 (zh)
DK0613608T3 (zh)
DK0553875T3 (zh)
DK0603481T3 (zh)
BR9304651A (zh)
DK0574087T3 (zh)
DK0657012T3 (zh)
DK0553681T3 (zh)
DK0588007T3 (zh)
DK0576346T3 (zh)
DK0564197T3 (zh)
TW227563B (zh)
DK0581726T3 (zh)
DK0576097T3 (zh)
DK0559942T3 (zh)
DK0590732T3 (zh)
TW250513B (zh)
BRPI9204323A2 (zh)
BR9304980A (zh)
AU1711092A (zh)
AU1842892A (zh)
AU2527592A (zh)
AU2619992A (zh)
AU2629492A (zh)